伊立替康联合雷替曲塞方案二线治疗晚期胃癌的临床研究

作者:谢晓素;顾康生 刊名:安徽医药 上传者:谢楚萍

【摘要】目的观察伊立替康(CPT-11)联合雷替曲塞二线治疗晚期胃癌的疗效及不良反应。方法对23例一线化疗方案治疗失败或缓解后再进展的晚期胃癌患者进行化疗,方案为伊立替康150 mg·m-290 min静滴D1;雷替曲塞3 mg·m-215 min静滴D1;3周为1个周期,2个周期后评价疗效。治疗期间进行不良反应评估。结果 23例均可评价毒副反应和远期疗效,其中22例患者均可评价近期疗效,有效率为54.54%,中位生存期为5个月(95%CI:3.8~6.2月)。常见毒副反应有中性粒细胞减少、贫血、恶性呕吐、血小板减少、迟发性腹泻等。结论伊立替康联合雷替曲塞在晚期胃癌二线治疗中有一定疗效,毒副作用可耐受,值得进一步临床研究。

全文阅读

伊立替康联合雷替曲塞方案二线治疗晚期胃癌的临床研究 谢晓素,顾康生 (安徽医科大学第一附属医院肿瘤内科,安徽 合肥 230022) 摘要:目的 观察伊立替康(CPT-11)联合雷替曲塞二线治疗晚期胃癌的疗效及不良反应。方法 对 23 例一线化疗方案治疗失败或缓解后再进展的晚期胃癌患者进行化疗,方案为伊立替康 150 mg·m -2 90 min 静滴 D1;雷替曲塞 3 mg·m -2 15 min 静滴 D1;3 周为 1 个周期, 2 个周期后评价疗效。治疗期间进行不良反应评估。结果 23 例均可评价毒副反应和远期疗效, 其中 22 例患者均可评价近期疗效,有效率为 54. 54%,中位生存期为 5 个月(95% CI:3. 8 ~ 6. 2月)。常见毒副反应有中性粒 细胞减少、贫血、恶性呕吐、血小板减少、迟发性腹泻等。结论 伊立替康联合雷替曲塞在晚期胃癌二线治疗中有一定疗效,毒副作用可耐受,值得进一步临床研究。关键词:雷替曲塞;伊立替康;胃癌;化学治疗 doi:10. 3969/j. issn. 1009 -6469. 2014. 08. 054 Irinotecan combined with raltitrexed as second- line chemotherapy for advanced gastric cancer:a clinical study XIE Xiao-su,GU Kang-sheng (Department of Oncology,The First Affiliated Hospital of Anhui Medical University,Hefei 230022,China) Abstract:Objective To observe the efficacy and toxicity of irinotecan plus raltitrexed as second-line treatment of advanced gastric cancer. Methods Twenty-three patients with advanced gastric cancer received CPT-11(150 mg·m -2 90 min ivgtt) on day 1 and raltitrexed(3 mg·m -2 15 min ivgtt) on day 1. One cycle lasted 21 days. After every two cycles,therapeutic efficacy was evaluated. Ad-verse reactions were assessed during treatment. Results Toxicity and overall survival could be evaluated in 23 patients. Response rate could be evaluated in 22 patients. The efficiency and disease control rate was 54. 54%. The median overall survival were 5 months (95%CI:3. 8 ~6. 2). Toxicities were mainly neutropenia,anemia,nausea,vomiting,thrombocytopenia and delayed diarrhea. Conclu-

参考文献

引证文献

问答

我要提问